We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Thermulon builds aerogels for building insulation and aspires to disrupt the global thermal building insulation market that was worth $30 billion in 2020. It claims that its aerogels are the first to beat the tradeoff between fire safety, thermal performance and price with the ability to fight climate and fire-safety emergencies. Thermulon cites its research with Ryder Architecture stating that using Thermulon's products on a new apartment block could save 100mm in insulation thickness compared to mineral wood and potentially add floor space equivalent to 7 additional 1-bed flats making safe insulation a profitable move for developers. The company was awarded £550,000 in InnovateUK equity-free grants, garnered a project to insulate 10,000 social houses over the next 5-10 years, and has been felicitated with awards from the Royal Society of Chemistry and the Royal Academy of Engineering. The company states it will use the investment to grow its team, file its first patent, certify its product and get Thermulon’s insulation on walls.
days to go: Expired investment: £949,033
TC BioPharm is an immunotherapy company. It has used its patented technology to harness the power of a particular part of the immune system, Gamma Delta T-cells (GDT), to negate cancer cells in the human body. TC BioPharm has treated terminally ill patients with acute myeloid leukaemia in approved clinical trials garnering positive responses from multiple patients. The company has received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to run a COVID-19 clinical trial to address the global pandemic. TC BioPharm aims to use its current technology to provide a frozen product that can be manufactured cost-effectively and distributed globally. The company has already raised over £7 million in the last 15 months. It will use the investment to take its clinical trials forward in COVID-19 and cancer.

Pitch Rated

59%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,753,067
Stericile Ltd is a chemical R&D company that has scientifically created a disinfectant meant to combat the epidemic of Hospital Acquired Infections. The company has achieved the biggest technological advancement in the peracetic acid market, having spent over £400,000 to create a unique chemical solution for the healthcare market. Stericile Ltd has secured a UK national supplier that caters to 15,000+ healthcare customers such as dentist & doctor surgeries, care homes, and medical centres with less effective products.
days to go: Expired investment: £229,200
Orthogem is a UK based manufacturer of synthetic bone grafts. Synthetic bone grafts are substitutes for human bone grafts and are designed to replace bone that has been lost. Orthogem have recently started to produce their product in a putty form in order to keep up with the changes in the market. 
days to go: Expired investment: £722,784
Nova is a world-leading and award-winning tidal energy company. It designs, builds, and operates tidal turbines that generate electricity from the flow of the tide and the natural ebb. Nova's underwater turbines work in harmony with marine environment and have zero visual impact. In 2018, Nova received international recognition at the G7 summit and won ‘Outstanding Project’ at the Green Energy Awards the same year. Nova aims to become cost-competitive with traditional baseload fossil fuels. With the proceeds, the company will fulfil its purpose of Business Growth (25%), Project Delivery (50%), and Commercial Readiness (25%).

Pitch Rated

56%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,255,666
Environmentally friendly roads created by replacing the oil-based bitumen with plastic from old rubbish and landfill, resulting in longer lasting, stronger and more durable roads. MacRebur roads are already in place and can be driven on in the UK and the firm is in advanced discussions and testing with international markets such as the USA, Canada and Australia. MacRebur supply their product to major asphalt companies including Aggregate, Cemex and Tarmac.
days to go: Expired investment: £3,171,989
MacRebur uses waste plastics destined for landfill or incineration and adding them into asphalt for road construction and surfacing to extend and enhance the bitumen (fossil fuel) binder. It argues that its carefully selected plastics, taken from the waste stream, are added into roads to improve strength and durability, whilst reducing the quantity of the oil-based bitumen used in a traditional road construction mix. MacRebur asserts that with each km of road laid using its MR products, the company sustainably uses up the equivalent weight of 740,541 one-time-use plastic bags. MacRebur has completed road tests in numerous countries including the UK and Europe, Turkey, Australia, and Japan to name a few. It has also signed agreements with India, the USA, Chile, Estonia, Kuwait, New Zealand, Switzerland, Bahrain, Spain, and Malaysia. The company will use the investment to build its manufacturing plants in five strategic locations across the world.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £3,055,740
Limits Technology has created a product at 50% of the cost of the competition. The Limits design is complete and ready for mass productions. The crowdfunding community received the company with more than 2K units promised from 66 countries by validating market demand. It aims to deliver the 100% compatible bicycle power meter for an affordable price. Limits Technology is raising investment to conduct initial manufacturing runs, push sales and marketing, identify and hire the main sales and support staff, and product development.
days to go: Expired investment: £160,330
Swiss-licensed medical cannabis producer, swisscann, targets the expansive €12 billion global medical cannabis market, with an EU distribution agreement already secured. Leveraging its THC-licensed production facility, the company aims to meet the rising demand for safe and effective medical cannabis products, boasting a cultivation license and a partnership with a publicly listed European pharmaceutical distributor. Strategically headquartered in Zurich, Switzerland, swisscann benefits from proximity to Germany, Europe's largest medical cannabis market projected to reach multibillion-Euro valuations by 2027. Anticipating availability in European pharmacies and an initial launch in the German market by Q1 2024, swisscann aims to establish its foothold in the European medical cannabis landscape.
days to go: Expired investment: £1,067,294
Please watch the video for more information
days to go: Expired investment: £360,250
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph